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ABSTRACT
Purpose: The infection is one of the main factors that affect the physiological evolution of the surgical wounds. The
aim of this work is to evaluate the effects of fibroblast growth factor (FGFâ) and anti-FGFâ in the healing, synthesis
and maturation of collagen when topically used on infected skin wounds of rats. Methods: An experimental study
was perfomed in 60 male Wistar rats. All animals were divided in two groups (A and B). Each group was divided in
three subgroups A1, B1; A2, B2 and A3, B3. After anesthesia with pentobarbital, two open squared wounds (1cm2),
4cm distant to each other, were done in the dorsal skin of all the rats. In group A (n=30) the wounds were contaminated
with multibacterial standard solution, and in group B(n=30) the wounds were maintained sterile. These wounds were
named F1 (for inflammation analysis) and F2 (for collagen study). The open wounds of A1 and B1 rats were topically
treated with saline solution, A2 and B2 were treated with FGFâ and subgroups A3 and B3 were treated with FGFâ and
anti-FGFâ. The rats were observed until complete epitelization of F2 wounds for determination of healing time and
the expression of types I and III collagen, using Picro Sirius Red staining. Inflammatory reaction in F1 wounds was
studied using hematoxilin–eosin staining. The three variable was measured by the Image Pro-Plus Média Cybernetics
software. The statistical analysis was performed by ANOVA and Tukey test, considering p<0.05 as significant.
Results: It was observed that infection retarded significantly (p<0.05) the time of wound scarring and the topical
application of FCFb reverted the inhibition of healing caused by bacteria. The inflammatory reaction was greater in
the subgroup B2 than in B1 and A3, and the difference was significant (p<0.05). It was observed greater expression
of type I collagen in all the subgroups treated with FCFb, when compared with the untreated subgroups. Type III
collagen was significantly decreased in wounds of B3 rats, comparing to the other subgroups. Conclusions: The
FCFb accelerated the healing of open infected wounds and contributed with maturation of collagen, enhancing the
type I collagen density. The anti-FCFb antibody was able to attenuate the production of both type I and III collagen.
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RESUMO
Objetivo: Avaliar os efeitos do fator de crescimento de fibroblastos básico (FCFâ) e do anti-FCFâ na cicatrização e
maturação do colágeno em feridas infectadas na pele de ratos. Métodos: Um estudo experimental foi realizado em 60 ratos
Wistar, divididos em dois grupos (A e B). Cada grupo foi divididos em 03 subgrupos A1,B1; A2,B2 e A3,B3. Após anestesia
com pentobarbital sódico intraperitoneal, foram feitas duas feridas abertas de 1cm2 na pele no dorso distando 4cm uma da
outra. Essas feridas foram denominadas feridas F1 (para análise inflamatória) e F2 (para estudo do colágeno).  No grupo
A(n=30), as feridas  foram contaminadas com solução multibateriana e no grupo B (n=30) as feridas não foram contaminadas.
As feridas receberam tratamento tópico com aplicação única. Nos subgrupos A1 e B1 foram tratadas com solução salina
tópica, as dos subgrupos A2 e B2 foram tratadas com o FCFâ e nos subgrupos A3 e B3 foram tratadas com FCFâ e com o
anti-FCFâ. Os dados formam analisados pelos testes ANOVA de Tukey, considerando p<0,05 como significante.   Resultados:
A infecção retardou de modo significante o tempo de cicatrização e a aplicação do FCFâ foi capaz de reverter a inibição da
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cicatrização provocada pela infecção(p<0.05). A resposta inflamatória foi maior nos grupos tratados com o FCFâ, e a
aplicação do anti-FCFâ inibiu a reação inflamatória(p<0.05). Houve aumento significante dos colágenos tipo I e III em
todos os subgrupos tratados com FCFâ, comparando com os não tratados, sendo a expressão do tipo I mais intensa do
que do tipo III (p<0.05). A aplicação do anti-FCFâ inibiu a expressão das moléculas do colágeno. Conclusões: O FCFâ foi
capaz de acelerar a cicatrização de feridas abertas infectadas e contribui para a maturação do colágeno, ao aumentar a
expressão do colágeno tipo I, fenômeno que foi atenuado pela ação do anti-FCFâ.
Descritores:  Fatores de crescimento de fibroblasto. Fibroblastos. Cicatrização de feridas. Pele. Infecção.
Introduction
The open surgical wounds heal mainly for two basic
mechanisms: contraction of the borders of the wounds
and migration of epithelial cells. The contraction reduces
the size of the total thickness of the operative wound
through centripetal movements of the skin surrounding
tissues. Afterwards the capillaries of the wound margins
form new vassels, migration of fibroblasts happens and
the wound will be fill out1,2,3. The contraction of the open
wounds depends on the capacity of the fibroblastos to
contract and move through the extracelular matrix. The
wounds contraction is influenced by many factors, such
as: steroids use, diabetes, avitaminosis and infection.
The infection is one of the main factors that alter the
physiologic evolution of the wound healing4,5,6. The
bacteria can affect the contraction of the wounds by
many mechanisms. Perry and Sutkin et al demonstrated
that the bacteria secrete exogen plasminogen activators,
and produce proteolitic enzymes that may affect the
extracelular matrix, blocking the wound contraction8. The
bacteria are capable to inhibit the angiogenesis, reducing
the two mechanisms of wound contraction9. It has been
demonstrated that the basic fibroblast growth factor
(FGFß) it is capable to revert the effects of the infection
on the contraction in open wounds in all of the phases of
the healing, through the fibroblasts formation and
migration. In spite of reducing the time of healing, some
studies demonstrated reduction in wounds strenght.
FGFß has been able to improve the healing of incisional
and open infected wounds by reducing its healing time,
and increasing the DNA synthesis in extracellular matrix,
without increasing the tensil strenght7,10. Broadley et al
demonstrated that the neutralization of FGFß for a specific
anti-body is capable to revert their functions, causing a
significant reduction of DNA, proteins and collagen
synthesis,  affecting the cytokines function11.  In
experiments with topical application of FGFß a significant
inhibition of the open wounds contraction was
observed12,13. Medeiros et al, as well as McGee et al,
observed that topical application of FGFß  in incisional
wounds increased significantly the density of collagen
and the tensil strength in rats  o submitted to infection,
steroids use, radiotherapy and imunossupressors14,15.
Several studies have demonstrated that FGFß acts in the
extracellular matrix stimulating angiogenesis, fibroblast
migration, angiogenesis and fibrogenesis, enhancing the
tensil strength and reducing the time for infected wounds
scaring3,4,5,6,7,8,9,10. So, the purpose of the present work
was to study the topical effect of FGFß and its anti-factor
on infected skin wounds of rats. We evaluated the
expression of types I and III collagen, as well as its
maturation, the time for wound scaring and the
inflammatory reaction in the involved tissues.
Methods
Sixty Wistar rats weighing 270±23g were used.
Animals were provided by the Nucleus of Experimental
Surgery of the Federal University of Rio Grande do Norte,
Brazil, with the approval of Ethics Committee in Research
(Animal Care). The International guidelines for the care
and use of laboratory animals were followed throughout
the study. The animais were  acclimatized to the research
laboratory for 7 days before we started the experiments.
Rats were housed under controlled illumination (12/12
hours light/dark cycle), humidity (60–70%), and
temperature (22°C). The animals were randomly separated
in groups and subgroups (Figure 1) and observed in
individual cages receiving water and food (Labina-
Purina®) ad libitum.
FIGURE 1 - Experimental design with distribution of 60 rats by groups and subgroups, and their treatments.
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After 12 hours of fasting, the rats were anesthetized
by intramuscular injection of 30mg/Kg of ketamine and
0,5mg/Kg of xylazine. Afterwards, dorsal skin depilation
and anti-sepsis with 1% povidone were performed. The
surgical procedures were performed under aseptic
conditions. Two open squared wounds (1cm2), 4cm
distant to each other, were done in the dorsal skin of all
the rats. These wounds were named W1 (for inflammation
analysis) and W2 (for collagen study).
Treatment of wounds
In group A (n=30), immediately after the surgical
procedure, the wounds were contaminated with the
topical application (figure 2) of multibacterial standard
solution (0,1ml of 1g of rats fresh feces and 1ml of saline).
In the following day, the infected wounds of the subgroup
A1 (n=10) were topically treated with 1 ml of saline
solution. The sub-group A2 (n=10) rats wounds were
treated with an unique dosis of FGF-ß 10ng diluted in
10ìl of  saline (Sigma, USA). In sub-group A3 (n=10) rats,
the wounds were topically treated with 10ng of FGF-ß +
anti-FGF-ß (figure 3).  In group B (n=30) rats, the wounds
were not contaminated and the same topical treatments
were accomplished as described to A.
Histological analysis
In the eighth postoperative day the W1 wound was
ressected and fixed in formaline 10% by 3 days. The biopsies
were processed following the routine  and stained with
hematoxilin and eosin (HE) for histological analysis of the
inflammatory reaction. The rats were observed until
complete epithelialization of W2 wounds for determination
of healing time. Under anesthesia, the wounds were
ressected and prepared to measure the expression of types
I and III collagen, using Picro Sirius Red (Direct Red 80 from
Aldrich Chemical Co, USA) staining and polarized filters.
The type I collagen was identified by its thick fibers and
compact and dense fibrils, yellow to light red colored. The
type III collagen formed green fine fibers with thin fibrils24.
The variables were analysed by the optical microscope
Olympus B-50 and the quantification of cells, fibers and
elements of the inflammatory reaction was performed by
the Image Pro-Plus Média Cybernetics software, LP, USA.
The statistical analysis was performed by ANOVA, t and
Tukey tests, considering p<0.05 as significant.
Results
Time for healing
The healing time of W2 infected wounds of subgroup
A1 was 21,5 days; in the subgroup A2, 12,87days, and 20,87
days in the subgroup A3. In the non-infected wounds of
subgroup B1 the healing time was 9,70 days, in the subgroup
B2 13,50 days, and in the subgroup B3 15,40 days (Table 1).
In infected wounds no treated with FGFb (subgroup A1)
the healing time was comparable to the A3 rats, whose
infected wounds were treated with FGFb and anti-FGFb
(p>0.05). When the infected wounds were treated with FGFb
(subgroup A2) we observed a significant reduction in the
healing time, when compared with A1 subgroup (p<0.05).
The same phenomenon was observed comparing the
subgroups B1 and B2, meaning that FGFb remarkably
contributed to accelerate the healing. The association of
anti-FGFb in infected and no infected wounds, inhibited
the beneficial effect of FGFb, as can be observed comparing
subgroups A2-A3 and B2-B3 (Table 1).
Histology
The density of inflammatory cells in the subgroup A3,
whose infected wounds were treated with FGFb and anti-
FGFb, was shorter than that observed in all the other
subgroups. The difference was significant when compared
the subgroup A3 to A2 and B2 (p<0.05). In the wounds
treated with FCFb, with and without infection (subgroups
A2, B2), the density of fibroblasts contributed to a great
density of inflammatory cells. (Table 2). The figures 4, 5 and
6 show histopathological details observed in the laminas of
their respective subgroups.
FIGURE 2 - Topical application of multibacterial solution
on W1 and W2 wounds of group A.
FIGURE 3 -Topical application of FGFβ.
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TABLE 1 - Expresses the mean of the healing time of the W2 wounds in each subgroup.
Healing time (days)*
A1 21,50 ± 1,60a
A2 12,87 ± 0,83b
A3 20,87 ± 1,64a
B1 13,50 ± 1,18c
B2 9,70 ± 1,70b
B3 15,40 ± 1,50d
*Mean ±standard deviation.
Values identified with the same letter do not differ (p>0,05).
Infection, no FGFβ
Infection + FGFβ
Infection + FGF² + Anti- FGFβ
No infection, no FGFβ
No infection + FGFβ
No Infection + FGF² + Anti- FGFβ
Subgroups TreatmentSubgroups
TABLE 2 - Mean of inflammatory cells and density of types I and III collagen. Histological analysis stained by HE and
picro-sirius red, respectively.
INFLAMMATION HE*1 COLLAGEN III2 COLLAGEN I *2
A 1 398,00 ± 211,51 153,64 ± 7,52** 186,97 ± 12,71**
A 2 519,87 ± 122,37 161,62 ± 8,63a** 193,28 ± 7,29**
A 3 307,37 ± 102,22b 139,14 ± 22,32a** 178,69 ± 29,89**
B 1 354,60 ± 120,08a 143,68 ± 9,03** 169,96 ± 12,23a**
B 2 603,62 ± 213,17ab 161,29 ± 7,75** 202,77 ± 18,77a**
B 3 497,50 ± 100,64 65,38 ± 14,92§** 174,25 ± 19,04**
Mean ± standard deviation
*Values identified with the same letter differ significantly. Tukey test, significance 0.05.
**Significant difference comparing types I and III collagen ( t test for pared data).
§ Differ significantly comparing with of subgroups (Tukey test, p<0.05).
1 – Number of inflammatory cells.
2 – Color density (green – red).
Infection, no FCFβ
Infection + FCFβ
Infecção + FCFβ + Anti-FCFβ
No infection, no FCFβ
No infection + FCFβ
No infection + FCFβ + Anti-FCFβ
Groups and treatment
Parameters
FIGURA 4 - Photomicrography of no infected wound treated
with FGFβ (subgroup B2), showing intense
inflammatory reaction. H-E, 100x).
FIGURA 5 - Photomicrography indicating low inflammatory
reaction in no infected wound of subgroup
B1 rat. H-E, 100x.
Qualitative and e quantitative analysis of  type I colllagen
The density of type I collagen of subgroup B2 rats
(treated with FGFb) was significantly higher (p<0.05) than
in subgroup B1, using multiple comparisons by the Tukey
test (Table 2). The figure 7 displays high density of collagen
type I in histological preparation of no infected wound of
subgroup B2, that can be compared with the low density
observed in the figure 8 (subgroup A1). When the anti-
FGFb was used in the wounds (subgroups A3, B3), the
density of the type I collagen had a significant reduction.
In the infected wounds, the treatment with FGFb (subgroup
A2) contributed to increase the density of the type I
collagen, comparing to the control (subgroup A1). However,
the differences in the density among those subgroups were
not significant (p>0,05).
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Analysis of type III collagen
Analyzing the expression of the type III collagen, it
was observed that FGFb didn’t stimulate its production in
infected and no infected wounds, when compared with the
controls (p>0.05). The treatment of wounds with anti-FCFß
reduced significantly the density of type III collagen when
those subgroups were compared with the wounds (A2, B2)
treated with FCFß (p<0.05).  The expression of the collagen
type I was always significantly greater than the observed
in type III collagen of all the other subgroups (Table 2).
The figure 9 demonstrates the low density of type III
collagen in infected wound of the subgroup B3, where rare
green fibers are seen. In figures 10 (subgroup A1), 11 (of
the subgroup A3) and 12 (subgroup B2), a high density of
the type III collagen is observed.FIGURE 6 - Photomicrography of infected wound treated with
FCFβ+anti-FCFβ (subgroup A3). H-E, 100x.
FIGURE 7 - Photomicrography of infected wound of
subgroup B2, treated with FCFβ. A high
density of type I collagen (red color) is
observed. (picro-sirius red, 200X).
FIGURE 8 - Photomicrography of no infected wound of
subgroup A1, showing low density of type I
collagen. (picro-sirius red, 200x).
FIGURE 9 - Photomicrography of no infected wound of
subgrupo B3 rat. Low density of type III
collagen (green collor). Picro-sirius red, 200x.
FIGURE 10 - High density of type III collagen (green) in no
infected wound of subgroup A1 rat. Picro-
sirius red, 200x.
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Discussion
Injury to the skin initiates a cascade of events
including inflammation, new tissue formation, and tissue
remodeling, which finally lead to reconstruction of the
wounded area16,17.  The repair process is initiated
immediately after injury by the release of various growth
factors, cytokines, and low-molecular weight compounds
from the serum of injured blood vessels and from
degranulating platelets. Disruption of blood vessels also
leads to the formation of the blood clot, which is
composed of cross-linked fibrin, and of extracellular matrix
proteins such as fibronectin,  tenascin,  and
thrombospondin16,17,18. The healing is an important
phenomenon of the surgical treatment, and involves
resistance of the sutured tissues, esthetics and recovery
of function. In the management of skin wounds these
aspects are essencial1,2,3,4. The experimental surgical
model used in this work allowed the analysis of the effects
of FGFb on inflammation and on expression of types I
and III collagen using the histochemical method with
picrosirius red staining, exposed to polarized light25,26.
Multiple studies have demonstrated a beneficial effect
of many growth factors, e.g., platelet-derived growth
factors (PDGFs), fibroblast growth factors (FGFs), and
granulocyte-macrophage colony stimulating factor (GM-
CSF) on the healing process, both in animal models and
also in patients suffering from different types of wound
healing disorders and infection27,28,29,30,31.  Using an only
dosis of 10µg/ml, they observed a reduction in the healing
time. In the same way, Hayward et al revealed that chronic
burns benefit with the topical application of FGFb (100µg/
ml)7.  The results of the present work revealed that the
infection affects the healing time delaying the scaring of
the open wounds, as seen in infected ones with no topical
treatment with FGFb, where the mean healing time was of
21,5 days. When the infected wounds were topically
treated with FGFb, the mean healing time was 12,8 days.
The exact biological mechanisms involving FGFs is
controversial. The roles of endogenous growth factors
in the healing response have been only partially
elucidated. However, in vivo functions of many growth
factors remain largely unconfirmed. The FGFs have a
broad mitogenic spectrum. They stimulate proliferation
of various cells of mesodermal, ectodermal, and also
endodermal origin. In addition to their mitogenic effects,
FGFs also regulate migration and differentiation of their
target cells,  and FGFs have been shown to be
cytoprotective and to support cell survival under stress
conditions32,33. Numerous in vivo effects of FGFs have
been demonstrated, which suggest a role of these growth
factors in wound repair. In particular, FGFb was shown
to stimulate angiogenesis in various assay systems34.
Furthermore, FGFs are mitogenic for several cell types
present at the wound site, including fibroblasts and
keratinocytes27. Thus FGFs are clear candidates for
contributing to the wound healing response, and this
hypothesis has been corroborated by a number of studies
where their local application stimulated tissue repair35.
Mcgee et al and Slavin et al observed acceleration of
wound healing time in diabetic rats, in chorticosteroid
use and in infected wounds with an isolated topical
application of FGFß. They observed increase in
angiogenesis, fibroblasts proliferation and great
deposition of collagen, comparing with controls15,23. In
clinical studies, it was made the topical use of FGFß in
chronic peptic ulcers, in decubitus ulcers and in ocular
lesions.  The authors observed reduction in healing time
and significant deposition of collagen in wounds21,24.
Medeiros et al observed that the topical application of a
single dose FGFß in sutured skin wounds of rats
stimulated the lymphocytes and fibroblasts proliferation,
increased the collagen synthesis and tensil strength of
wounds14. However, Stenberg et al, using a similar
experimental design of the present work, demonstrated
that FGFß enhances infected wounds, but does not
FIGURE 11 - Photomicrography of infected wound treated
with FCFβ+anti-FCFβ, subgroup A3. A high
density of type III collagen is shown. (picro-
sirius red, 200x).
FIGURE 12 - Photomicrography of no infected wound
treated with FCFβ (subgroup B2). A high
density of type III collagen is shown (picro-
sirius red, 200x).
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increase tensil strength10. The collagen fibers are
important components of the extracelular matrix,
responsible for the tensil resistance of the wounds3,5,12.
The role of FGF in wound repair was finally clarified when
FGF null mice were used for wound healing studies.
When they were challenged by full-thickness excisional
wounding, they showed delayed healing35. In addition
to a retardation in the rate of reepithelialization, mice null
for FGF2 showed reduced collagen deposition at the
wound site, and they had thicker scabs35. The tensil
strength of operative wounds depends on some factors,
such as the collagen level and the thickness and
organization of their fibers1. It was demonstrated in the
present work that the topical application of FGFß
stimulated the deposition of types I and III collagen as
observed in other studies14,15. The concomitant use of
FGFß and anti-FGFß antibody in open infected and clean
wounds inhibited the collagen synthesis. To provide
functional evidence for a role of FGF in wound repair,
Broadley et al11 used a neutralizing polyclonal antibody
that was raised against human FGF. They incorporated
the purified IgG into sponge disk, and the disks were
then implanted subcutaneously under ventral panniculus
carnosus of rats. The continuous release of the antibody
caused a striking reduction in cellularity and
vascularization compared with the granulation tissue
formed in the control IgG sponges. In addition, DNA,
protein, and collagen levels in the anti-FGF sponges were
reduced by 25–35% relative to control at day 7 after
implantation. This study strongly suggested an important
role of endogenous FGF in wound repair. The application
of FCFß increased the global synthesis of the collagen,
in higher intensity the type I than type III collagen. This
finding must have contributed strongly to the maturation
of collagen corroborated by several studies
2,3,4,7,12,14,15,36,37,38,39,40,41.
Conclusion
The topical treatment with FCFb influenced the
evolution of infected and clean skin wounds of rats. The
healing time was accelerated, the inflammatory reaction was
favorable as well as the deposition of I and III collagen. The
antibody anti-FCFb neutralized the FCFb effects.
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